Home > BIGG > Search result

    Results: 4

    GRADE: 15-valent pneumococcal conjugate vaccine (PCV15) use in children aged <2 years

    MMWR recomm. rep; 71 (37), 2022
    On June 22, 2022, ACIP recommended use of 15-valent pneumococcal conjugate vaccine (PCV15 [Vaxneuvance, Merck Sharp & Dohme LLC]) as an option for pneumococcal conjugate vaccination for persons aged <19 years according to currently recommended PCV13 dosing and schedules. A systematic review and Grading o...
    Pneumococcal Infections/immunology, Heptavalent Pneumococcal Conjugate Vaccine/therapeutic use, Immunogenicity, Vaccine
    Fulltext

    Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) for Pneumococcal Vaccines for Adults aged ≥65 years

    MMWR recomm. rep; 63 (37), 2014
    GRADE was used to evaluate 13-valent Pneumococcal Conjugate Vaccine (PCV13) for routine use among adults aged ≥65 years. Evidence of benefits, harms, values and preferences, and cost-effectiveness were reviewed in accordance with GRADE methods.[1] The primary policy question was “Should PCV13 be adm...
    Pneumococcal Vaccines/therapeutic use, Pneumococcal Infections/immunology, Pneumococcal Vaccines/adverse effects, Immunogenicity, Vaccine
    Fulltext

    Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) of Pneumococcal Vaccines for Immunocompromised Children Aged 6 through 18 Years

    MMWR recomm. rep; 62 (25), 2013
    GRADE was used to evaluate 13-valent Pneumococcal Conjugate Vaccine (PCV13) for routine use among immunocompromised children aged 6 through 18 years. Evidence of benefits, harms, values and preferences, and cost-effectiveness were reviewed in accordance with GRADE methods.[1] The primary policy question...
    Pneumococcal Vaccines/therapeutic use, Immunocompromised Host, Pneumococcal Infections/immunology, Anemia, Sickle Cell/immunology, HIV Infections/immunology, Immunogenicity, Vaccine
    Fulltext

    Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) for Pneumococcal Vaccines for Immunocompromised Adults

    MMWR recomm. rep; 61 (40), 2012
    GRADE was used to evaluate 13-valent Pneumococcal Conjugate Vaccine (PCV13) and 23-valent pneumococcal polysaccharide vaccine (PPSV23) for routine use among immunocompromised adults. Evidence of benefits, harms, values and preferences, and cost-effectiveness were reviewed in accordance with GRADE methods...
    Pneumococcal Vaccines/therapeutic use, Pneumococcal Infections/immunology, Immunocompromised Host, Immunogenicity, Vaccine
    Fulltext